Drug Trial Radar · NCT07143604
A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Actual
Start
Aug 29, 2025
Primary completion
Aug 14, 2026
Study completion Sep 28, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
AZD0901Drug
Participants will receive AZD0901 IV, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: At month 6 after date of first dose
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Chelyabinsk, Russia
Research Site
Krasnoyarsk, Russia
Research Site
Kuzmolovskiy, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Volgograd, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.